Huibin Yue

机构：Amgen (United States)

发表论文 88 篇 · 总被引 2931 次 · h-index 18

代表论文

Temporary Expression of concern: “Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial” [Annals of the Rheumatic Diseases, Volume 83, Issue 2, February 2024, Pages 223–232] (2023 · Annals of the Rheumatic Diseases · 被引 48)
Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy (2024 · Journal of the American Society of Nephrology · 被引 39)
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial (2023 · The Lancet Rheumatology · 被引 31)
Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Combined Data From Three Clinical Trials (2025 · ACR Open Rheumatology · 被引 17)
The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial (2023 · The Lancet Rheumatology · 被引 12)
Corrigendum to “The Glucocorticoid Toxicity Index: Measuring Change in Glucocorticoid Toxicity Over Time” [Seminars in Arthritis and Rheumatism 55 (2022):152010] (2024 · Seminars in Arthritis and Rheumatism)